Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by aliasunknownon Mar 07, 2018 11:42am

152 Views

Post# 27675821

RE:RE:RE:RE:RE:Picked up another 40k at 24c

Shorts update

Trading Status:	TRADING	Ex Dividend:	N
Type:	EQUITY	Currency:	CDN
Sub Type:	COMMON	Market Tier:	Tier2
Listed Date:	18/Jun/2013

Security Description/Comments

New Listing-IPO -shares

Short Summary
Short Volume	As Of
940,790	28/Feb/2018
289,126	15/Feb/2018
442,429	31/Jan/2018

Trading History
	This Week	This Month	This Year	Last Year
High:	0.260	0.270	0.330	0.285
Low:	0.235	0.235	0.150	0.080
Close:	0.250	0.250	0.250	0.145

All Time Records
High:	0.880	07/Mar/2014	Volume:	9,932,618	16/Jan/2015
Low:	0.040	26/Jan/2015	Value:	1,241,225.70	20/Feb/2018
			# Trades:	765	16/Jan/2015